Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · October 08, 2024

Identifying Baseline Serum and Stool Microbiome Biomarkers Predicting the Outcomes of Ritlecitinib Induction Therapy in Patients With Ulcerative Colitis

Journal of Crohn's & Colitis

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Crohn's & Colitis
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis
J Crohns Colitis 2024 Sep 03;18(9)1361-1370, M Hassan-Zahraee, Z Ye, L Xi, E Dushin, J Lee, J Romatowski, J Leszczyszyn, S Danese, WJ Sandborn, C Banfield, JD Gale, E Peeva, RS Longman, CL Hyde, KE Hung

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading